Drotrecogin alfa | |||
---|---|---|---|
Cumulative survival | PROWESS | ADDRESS | Point estimate Pooled results (± SD) |
28-day | 69.1% [2] | 70.5%[14] | 69.45% (± 3.55) |
3-month | 58.9% [8] | NA | 58.9% (± 2.42) |
6-month | 55.2% [8] | NA | 55.2% (± 2.44) |
12-month | 52.1% [8] | NA | 52.1% (± 2.46) |
30-month | 45.6% [8] | NA | 45.6% (± 2.45) |
Placebo | |||
Cumulative survival | PROWESS | ADDRESS | Pooled results (± SD) |
28-day | 56.3% [2] | 75.3% [14] | 62.93% (± 3.40) |
3-month | 48.4% [8] | NA | 48.4% (± 2.49) |
6-month | 45.3% [8] | NA | 45.3% (± 2.48) |
12-month | 41.3% [8] | NA | 41.3% (± 2.45) |
30-month | 33.8% [8] | NA | 33.8% (± 2.36) |